Trial Profile

A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BO 112 (Primary) ; Nivolumab (Primary)
Indications Dermatofibrosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Adverse reactions

Most Recent Events

24 Feb 2025 Planned End Date changed from 31 Jan 2026 to 31 Jan 2027.
24 Feb 2025 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.
28 Feb 2024 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com